# Diabetes Research Hub — Monitor Report

**Run date:** 2026-07-01 (automated, scheduled)
**Previous monitor report:** 2026-06-30
**Data freshness:** Trials + PubMed pulled 2026-07-01 02:06; gap analysis 2026-06-30 02:13

---

## File System Status

Core pipeline is healthy and current. All four expected script outputs are present:

| File | Last modified | Status |
|------|---------------|--------|
| clinical_trials_latest.json | 2026-07-01 02:06 | Fresh |
| pubmed_recent_latest.json | 2026-07-01 02:06 | Fresh |
| literature_gap_data.json / report | 2026-06-30 | Fresh (1 day) |
| hub_monitor_report.md | 2026-07-01 02:10 | Fresh |

hub_monitor.py tracked 998 files this scan: 3 new, 30 modified, 0 removed. The "761 files older than 14 days" flag is expected — those are the historical daily snapshot archives (667 .json files total), not stale live data. No missing or genuinely stale pipeline outputs.

---

## Clinical Trial Changes

**Corpus:** 837 unique trials. Automated snapshot diff (06-30 → 07-01): **5 new, 7 removed, 0 status changes.**

New trials:
- **NCT06010004** (Eli Lilly) — Orforglipron long-term safety, T2D — **COMPLETED with results posted 2026-06-30**
- NCT05756361 (SUNY) — Family-Based Treatment for T1D — COMPLETED with results
- NCT07675499 (Rutgers) — Exercise + intranasal insulin, T2D — Phase 2/3 recruiting
- NCT06601166 (Dexcom) — CGM in T2D
- NCT07675161 (Medtronic MiniMed) — MiniMed Fit pediatric device study

Removed (7): mostly recruiting device/SGLT2 studies (Endogenex, HRS-7535, OpenAPS, Medtrum, NT-0796) — likely status reclassification or query drift, not necessarily terminations. Worth spot-checking if any were tracked.

*Note:* the hub script reported "new results posted: 0" because the two trials that posted results (NCT06010004, NCT05756361) are **new to the corpus**, so their results arrived with them rather than as a status change on an existing trial.

### Phase 3 trials to watch (47 recruiting Phase 3 total)

Highest-priority by our doctrine (T1D cure / immunotherapy / novel mechanism):

| NCT | Sponsor | Focus |
|-----|---------|-------|
| NCT06832410, NCT04786262 | **Vertex** | VX-880 / zimislecel islet cell therapy (incl. kidney-transplant cohort) — recruiting |
| NCT07222332, NCT07222137 | **Eli Lilly** | Baricitinib to preserve beta-cell function / delay Stage 3 T1D — recruiting |
| NCT07088068 | **Sanofi** | Teplizumab head-to-head Phase 3 — recruiting |
| NCT06334133 | vTv Therapeutics | Cadisegliatin (glucokinase activator) adjunct to insulin, T1D |
| NCT07076199 | **Novo Nordisk** | Weekly insulin icodec, recruiting |
| NCT07564414 | **Novo Nordisk** | CagriSema dose comparison, recruiting |
| NCT07548996 / NCT07258394 | Nanjing Medical Univ. | Dimethyl fumarate to preserve islet β-cell function (two Phase 3s) |

Key-org footprint: Vertex 2 Phase 3 recruiting + VX-264 Phase 1/2 (active). Lilly and Novo dominate the T2D incretin Phase 3 pipeline (retatrutide, orforglipron, efsitora, CagriSema, icodec). Sana Biotechnology: no trials currently in corpus.

### Recently posted results worth review (last 30 days)
- **NCT06010004** — Orforglipron long-term safety, T2D (Lilly, 06-30)
- NCT01897688 — Phase 3 islet transplantation (06-18)
- NCT04776239 — Allogeneic MSC infusion for diabetes (06-16)
- NCT04965935 — SGLT2i in kidney disease (06-08)

---

## PubMed Highlights

168 unique papers across 16 domains (30-day lookback). Snapshot diff: **34 new, 28 dropped.**

**Cross-domain papers (12 — highest value):**
- **Teplizumab cluster (4 papers)** — Expanded indication / Tzield reviews across JAAPA, Frontiers in Immunology, Lancet D&E, Medical Letter. Signals the expanded-indication story is propagating through clinical literature.
- **[42296503]** Orforglipron + retatrutide comparative benefit/harm analysis — *Annals of Internal Medicine* (bridges two key therapies).
- **[42366647]** CagriSema dual-chamber pen usability — *J Diabetes Sci Technol*.
- **[42372727]** Microbiome × immune cells in metabolic homeostasis — *Cell Metabolism*.
- **[42357829]** CGM-centred glycaemic-variability framework — bridges T2D Remission × Closed-Loop AP.

**Key-therapy tracking:** dapagliflozin 68 mentions, orforglipron 13, teplizumab 10, CagriSema 8, icodec 7, retatrutide 5, baricitinib 5, **zimislecel 0** (still no indexed publications — watch for the pivotal-trial readout).

**Domain volume:** AI/ML (260), T2D GLP-1 (255), Microbiome (200) lead. Thinnest: Drug Repurposing (6), GLP-1 Pharmacogenomics (1), Epigenetics (9) — consistent with our identified gaps.

---

## Gap Analysis Summary

Top 5 under-researched intersections (Gap Score 100, BRONZE — single-source, needs expert confirmation):

1. **Beta Cell Regen × Health Equity** (0 joint pubs) — who accesses regenerative therapies is unstudied
2. **Insulin Resistance × Islet Transplant** (1) — IR effect on graft survival barely studied
3. **Islet Transplant × Drug Repurposing** (0) — computational screening of immunosuppressants for islet protection
4. **Islet Transplant × Health Equity** (0) — access equity at select-center therapies
5. **Gene Therapy × LADA** (0) — LADA autoimmune mechanism as gene-therapy candidate

**Tier 1 alignment:** Intersections #3 (Drug Repurposing) and Beta Cell Regen / Islet Transplant clusters map to Tier 1 computational-contribution areas in RESEARCH_DOCTRINE.md (omics integration, network analysis, drug screening). These are the strongest "compute-first" opportunities — unchanged from the 06-30 run.

---

## Breaking News (web check, last 7 days)

**Nothing genuinely new this week.** Context-setting only:
- Orforglipron (Foundayo, Lilly) was FDA-approved **April 1, 2026** for chronic weight management — not a new event; the June corpus activity reflects follow-on trial results and literature, not a fresh approval.
- Vertex zimislecel remains on track for **2026 global regulatory submission**; no FDA action in the last 7 days.
- ADA 86th Scientific Sessions (New Orleans, June 5–8) already reflected in the corpus.

No Phase 3 topline readouts, FDA approvals, or major journal events in the trailing 7 days that aren't already captured.

---

## Recommended Actions

1. **Review Orforglipron long-term safety results** (NCT06010004, posted 06-30) — extract endpoints for the T2D incretin tracker; log evidence level per doctrine.
2. **Spot-check the 7 removed trials** — confirm whether Endogenex (NCT07197788) and OpenAPS (NCT06081231) dropped due to status change vs. query drift before deleting from any tracked list.
3. **Gap analysis is current (1 day old)** — no re-run needed. Next scheduled refresh sufficient.
4. **Watch zimislecel publication tracker** — still 0 indexed papers; the pivotal-trial readout will be the trigger event. Vertex Phase 3 trials (NCT06832410 / NCT04786262) are the ones to monitor.
5. **Cross-domain paper to log:** [42296503] orforglipron vs. retatrutide (Annals) — relevant to T2D GLP-1 and our incretin comparative-effectiveness thread.

---

*Generated by diabetes-hub-monitor (scheduled). Review run only — no existing files modified. Gap classifications are BRONZE and require expert validation per Research Doctrine v1.0.*
